Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Eluxadoline is approved by the Food and Drug Administration for the treatment of adults with irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline is a locally acting mixed μ-opiod and κ-opioid receptor agonist and δ-opioid receptor antagonist. The abuse potential of eluxadoline was evaluated as part of the Phase 2 and 3 clinical trials assessing the efficacy, safety, and tolerability of the drug.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Gastroenterol. Hepatol.

Title: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Publisher: Elsevier BV

ISSN (Electronic): 1542-7714

ISSN (Print): 1542-3565

Publication date (Electronic): Jul 2017

Volume: 15

Issue: 7

Affiliations

[1 ] Pinney Associates, Bethesda, Maryland. Electronic address: rfant@pinneyassociates.com.

[2 ] Pinney Associates, Bethesda, Maryland.

[3 ] Digestive Health Center, University of South Alabama, Mobile, Alabama.

[4 ] Former employee of Furiex Pharmaceuticals, Inc, an affiliate of Allergan plc, Parsippany, New Jersey.

Article

Publisher Item ID: S1542-3565(17)30134-9

DOI: 10.1016/j.cgh.2017.01.026

PubMed ID: 28167156

SO-VID: fa559e8e-fc91-4181-bfc7-e790d5102832

History

Keywords: Addiction,Enteric Nervous System,SOWS,Viberzi

Data availability:

Keywords: Addiction, Enteric Nervous System, SOWS, Viberzi

Comments

Comment on this article

scite_

Cited by 9

See all cited by

Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.

Read this article at